drugset / Trial / NCT00202917

Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies

NCT00202917

Phase 1/2 Completed 61 enrolled University Hospital Tuebingen
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to study the feasibility and Toxicity of allogeneic haploidentical hematopoietic cell transplantation with CD3/CD19 depleted stem cells and a dose reduced conditioning.

Timeline

Start
2004-02
Primary completion
2009-07
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Background Fludarabine Small molecule
Background Melphalan Small molecule
Background Thiotepa Other / unclassified
Background muromonab-CD3 Monoclonal antibody